Dec 05, 2012, 11.07 AM | Source: PTI
The Supreme Court today reserved its order on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India.
A bench of justices Aftab Alam and Ranajan Prakash Desai reserved its verdict after marathon arguments which went on for months.
Novartis approached the apex court challenging the order of Chennai-based Intellectual Property Appellate Board (IPAB), which rejected its appeal against patent department's decision on Glivec.
The Comptroller General of Patent and Design had denied patent to Glivec on several grounds including its alleged failure to meet stipulations under sections 3(d) and 3(b) of the Indian Patent Law.
Section 3(d) restricts patents for already known drugs unless the new claims are superior in terms of efficacy.
Section 3(b) restricts patents for products that are against public interest and do not demonstrate enhanced efficacy over existing products.
Novartis India stock price
On May 30, 2016, Novartis India closed at Rs 722.00, down Rs 2.8, or 0.39 percent. The 52-week high of the share was Rs 982.00 and the 52-week low was Rs 600.00.
The company's trailing 12-month (TTM) EPS was at Rs 62.14 per share as per the quarter ended March 2016. The stock's price-to-earnings (P/E) ratio was 11.62. The latest book value of the company is Rs 375.65 per share. At current value, the price-to-book value of the company is 1.92.
It had posted a net profit of Rs 51.94 crore for t
The company's board meeting is scheduled to be hel
HeidelbergCement India has reported a sales turnov
Medi-Caps has reported a sales turnover of Rs 6.77
When you unplug you mind for a minute, you restore
Reliance Infra posted its third quarter results. N
Himalaya's Ravi Prasad talks about the contrarian